Private Ozurdex (dexamethasone) DME treatment cost UK 2026

What is Ozurdex?

Ozurdex (dexamethasone 0.7 mg intravitreal implant, AbbVie/Allergan) is a biodegradable sustained-release steroid drug delivery system designed specifically for the vitreous cavity. The implant is a small cylindrical rod of poly-lactic-co-glycolic acid (PLGA) copolymer measuring approximately 0.46 millimetres in diameter and 6 millimetres long, containing 700 micrograms of preservative-free dexamethasone. After intravitreal placement the PLGA matrix hydrolyses progressively to lactic acid and glycolic acid (which the eye safely metabolises to carbon dioxide and water) while releasing dexamethasone in a biphasic profile: a higher initial peak over the first 4 to 6 weeks, followed by a maintenance phase that lasts approximately 4 to 6 months in most eyes. Vitrectomised eyes may experience slightly faster clearance.

The pharmacological action of dexamethasone is broader than anti-VEGF therapy. Dexamethasone suppresses vascular endothelial growth factor (VEGF), but also the pro-inflammatory cytokines interleukin-6, interleukin-8, monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1) and tumour necrosis factor alpha (TNF-α), as well as stabilising endothelial tight junctions to restore the blood–retinal barrier. This multi-pathway mechanism is particularly relevant in diabetic macular oedema, where inflammation is a substantial driver of macular thickening alongside VEGF-mediated permeability, and in macular oedema secondary to retinal vein occlusion and non-infectious posterior uveitis where inflammation is the dominant pathology.

Ozurdex is licensed in the United Kingdom and Europe (and FDA-approved in the United States) for three indications: diabetic macular oedema in pseudophakic eyes and in phakic eyes inadequately responsive to or unsuitable for non-corticosteroid therapy (NICE TA349, 2015; with updated TA824 review for selected populations); macular oedema secondary to branch retinal vein occlusion or central retinal vein occlusion (NICE TA229); and non-infectious uveitis affecting the posterior segment (NICE TA460). It is delivered as a single-use 22-gauge applicator that introduces the solid PLGA rod through the pars plana 3.5 to 4.0 millimetres posterior to the limbus in the supero-temporal or infero-temporal quadrant, with the rod settling into the inferior vitreous cavity over minutes to hours.

UK 2026 Ozurdex pricing, in detail

Private Ozurdex pricing in the UK is driven by the centre's CQC-registered clean room overhead and consultant medical retina seniority, the procurement cost of the Ozurdex implant (manufacturer list price approximately £870 plus VAT), the OCT and where indicated OCT angiography included in the visit, and the monitoring schedule (typically a 4-week post-implant review with OCT, and re-implantation decisions on a 4 to 6 monthly cadence based on OCT macular thickness and visual acuity). Most reputable London providers bundle these components into an all-inclusive per-implant fee.

For related medical retina pricing and pathways see our private faricimab (Vabysmo) injection cost UK, our private anti-VEGF wet AMD injections London, our macular degeneration condition guide and our macular degeneration treatments overview.

What a quality UK Ozurdex DMO package should include

• Consultant medical retina specialist — a UK GMC-registered consultant ophthalmologist with documented medical retina fellowship, active diabetic eye disease and uveitis practice and a minimum 100 intravitreal procedures per year.
• Full pre-injection work-up — best corrected visual acuity, slit-lamp dilated fundus examination, Goldmann or non-contact tonometry, spectral-domain OCT of the macula (assessing central subfield thickness, intra-retinal cysts, sub-retinal fluid, hard exudates, disorganisation of retinal inner layers DRIL, ellipsoid zone integrity, posterior hyaloid status), and OCT angiography where appropriate to map the foveal avascular zone, microaneurysms and capillary non-perfusion.
• CQC-registered clean room or sterile minor procedure room — with laminar flow, dedicated injection chair, and immediately available indirect ophthalmoscope, sterile lid speculum, povidone iodine 5 per cent and tonometer.
• Topical anaesthetic technique — proxymetacaine and tetracaine drops instilled three to four times over 5 to 10 minutes, supplemented by sub-conjunctival or peri-conjunctival lidocaine 2 per cent where the patient is anxious or sensitive.
• Povidone iodine 5 per cent — applied to the conjunctiva and lid margin pre-injection (the single most important infection-prevention step; without povidone iodine endophthalmitis rates rise approximately 10-fold).
• The Ozurdex 22-gauge applicator — supplied as a single-use sterile injector by AbbVie/Allergan; the device cost is non-negotiable and should be itemised.
• Post-injection IOP measurement — immediately after the implant, central retinal artery perfusion confirmed by indirect ophthalmoscopy or finger-count vision check; transient post-injection IOP spikes are common but settle within minutes.
• Same-day discharge with patient information — including topical antibiotic drops (chloramphenicol four times a day for 24 to 48 hours per local protocol), 7-day endophthalmitis symptom warning (sudden pain, severe redness, vision loss, floaters, photophobia), and a written re-treatment plan with the next OCT review date.
• 4-week post-implant OCT review — consultant retina-led OCT macula and IOP check at week 4 to confirm response (typically a substantial reduction in central subfield thickness within the first 4 weeks).

Evidence base — what the trials show

Ozurdex has the largest sustained-release steroid evidence base of any intravitreal device in 2026, spanning diabetic macular oedema, retinal vein occlusion macular oedema and posterior uveitis. The headline trials and key real-world data should be reviewed together:

• MEAD (Boyer et al., Ophthalmology 2014; 1,048 eyes, 3-year RCT) — two pivotal phase 3 trials of Ozurdex 0.7 mg every 6 months versus sham in DMO. Primary endpoint ≥15 ETDRS letter gain at 3 years: 22.2 per cent Ozurdex versus 12.0 per cent sham. Mean BCVA gain at 3 years approximately 3 letters Ozurdex versus 2 letters sham; mean central subfield thickness reduction substantially greater in the Ozurdex arm.
• MEAD pseudophakic subgroup — in eyes already pseudophakic at baseline (and therefore not penalised by cataract progression), Ozurdex outcomes were closer to anti-VEGF, supporting the NICE TA349 licensing in pseudophakic DMO.
• BEVORDEX (Gillies et al., Ophthalmology 2014; 88 eyes, 2-year RCT) — Ozurdex versus bevacizumab (Avastin) in DMO. Visual outcomes broadly similar (40 per cent versus 41 per cent gained ≥10 letters), with markedly fewer injections in the Ozurdex arm (2.7 vs 8.6 over 2 years) and superior anatomic reduction in central subfield thickness.
• GENEVA (Haller et al., Ophthalmology 2010; 1,267 eyes, 12-month RCT) — pivotal phase 3 trials of Ozurdex versus sham in BRVO and CRVO macular oedema. Time to 15-letter improvement significantly faster in Ozurdex; supported NICE TA229 licensing.
• HURON (Lowder et al., 2011) — phase 3 RCT of Ozurdex versus sham in non-infectious posterior uveitis; supported NICE TA460 licensing.
• CHAMPLAIN (Boyer et al., 2011) — prospective study of Ozurdex in vitrectomised eyes with persistent DMO; demonstrated efficacy with slightly faster clearance, supporting use in this otherwise difficult-to-treat group.
• DRCR Protocol U (2018, sub-analysis) — ranibizumab plus combined dexamethasone implant versus ranibizumab alone in suboptimally responding DMO; combined arm achieved superior anatomic reduction in central subfield thickness but no statistically significant BCVA difference at week 24, with higher rates of IOP elevation in the combined arm.
• Real-world UK and European data (Bailey et al., 2017; Iglicki et al., RWE 2019–2024) — congruent with trial data; particularly strong outcomes in pseudophakic DMO, vitrectomised DMO, and DMO with significant inflammatory OCT biomarkers (hyperreflective foci, DRIL).
• Safety pooled analysis — cataract progression in phakic eyes 60 to 70 per cent at 3 years (versus 21 per cent sham); IOP rise >25 mmHg in 15 to 30 per cent (controllable with topical drops in >95 per cent; <1 per cent require glaucoma surgery); endophthalmitis rate <0.05 per cent per injection with povidone iodine prep; rare anterior chamber implant migration in aphakic or compromised zonule eyes.

In short: Ozurdex is the most evidence-supported sustained-release steroid for DMO in 2026. It is genuinely competitive with anti-VEGF in pseudophakic and vitrectomised eyes and in DMO with strong inflammatory features, while accepting a higher cataract-progression and IOP-rise penalty in young phakic eyes — which is why anti-VEGF remains first-line in that subgroup.

Ozurdex versus anti-VEGF, Iluvien and other DMO treatments

The right DMO treatment depends on the lens status, the OCT pattern (intra-retinal cysts versus diffuse thickening versus inflammatory biomarkers), the response to prior anti-VEGF, the patient's injection-clinic burden tolerance, cardiovascular comorbidities and any inflammatory or vasculitic features. Honest head-to-head comparison:

• Ozurdex versus anti-VEGF (faricimab Vabysmo, aflibercept Eylea / Eylea HD, ranibizumab Lucentis, bevacizumab Avastin) — anti-VEGF remains first-line in young phakic DMO. Ozurdex matches or exceeds anti-VEGF in pseudophakic, vitrectomised and recalcitrant DMO; produces faster initial anatomic dry-out; and substantially reduces injection burden (2 to 3 implants per year versus 5 to 7 anti-VEGF). DRCR Protocol U showed combined ranibizumab plus Ozurdex was superior anatomically but not visually, with higher IOP rise. In 2026 the typical pathway is anti-VEGF first; Ozurdex switch or augmentation in suboptimal responders.
• Ozurdex versus Iluvien (fluocinolone acetonide 190 mcg) — Iluvien is a non-biodegradable polyimide implant releasing fluocinolone over 36 months; reserved for chronic recalcitrant pseudophakic DMO unresponsive to anti-VEGF and Ozurdex. Iluvien achieves longer duration but with substantially higher IOP rise (~30 per cent require IOP-lowering surgery) and ~80 per cent cataract progression. Ozurdex is preferred for first-line steroid trial; Iluvien is reserved for proven Ozurdex responders who cannot tolerate the re-implantation cadence.
• Ozurdex versus intravitreal triamcinolone (Kenalog 4 mg, off-label) — triamcinolone is a much older steroid option, shorter acting (approximately 3 months), associated with higher peak IOP spikes and a higher pseudo-endophthalmitis rate (sterile suspension migration into the anterior chamber). Largely superseded by Ozurdex.
• Ozurdex versus macular focal/grid laser — laser is now rarely first-line in centre-involving DMO; useful adjunct in residual non-centre-involving edge oedema or persistent microaneurysm leakage on fluorescein angiography.
• Ozurdex versus pars plana vitrectomy with ILM peel — vitrectomy is reserved for refractory DMO with vitreomacular traction, epiretinal membrane or chronic recalcitrant disease where pharmacologic options are exhausted; vitrectomy accelerates Ozurdex clearance and may reduce sustained-release benefit.
• Ozurdex combination strategies — emerging real-world data (Iglicki RWE 2019–2024) support OCT-guided switch from anti-VEGF to Ozurdex in suboptimal responders, particularly where OCT shows hyperreflective foci, DRIL, or persistent intra-retinal cysts despite anti-VEGF; some centres combine Ozurdex with subsequent anti-VEGF as needed.

For the parallel anti-VEGF pricing and pathway see our private faricimab (Vabysmo) injection cost UK and anti-VEGF injections overview.

Who is a good candidate for Ozurdex?

Ozurdex is licensed and clinically appropriate in:

• Pseudophakic eyes with centre-involving DMO (NICE TA349 first-line steroid licensing).
• Vitrectomised eyes with persistent DMO where anti-VEGF clearance is accelerated.
• Phakic eyes with centre-involving DMO inadequately responsive to or unsuitable for non-corticosteroid therapy (NICE TA349 second-line in phakic eyes).
• Centre-involving DMO with strong inflammatory OCT biomarkers (hyperreflective foci, disorganisation of retinal inner layers, sub-retinal fluid out of proportion to angiographic leakage).
• Patients with cardiovascular contraindications to anti-VEGF (recent arterial thromboembolic event, stroke, MI in the prior 3 months on case-by-case basis).
• Patients with significant injection-clinic burden tolerance issues or geographic difficulty attending monthly anti-VEGF schedules.
• Macular oedema secondary to BRVO and CRVO (NICE TA229).
• Non-infectious posterior uveitis with cystoid macular oedema (NICE TA460).

Relative or absolute contraindications include active ocular or peri-ocular infection (preseptal cellulitis, infectious conjunctivitis), advanced glaucoma with poor IOP control where steroid-induced IOP rise is unacceptable, known hypersensitivity to dexamethasone, aphakia or compromised lens-iris-zonule diaphragm where implant migration to the anterior chamber is a risk, pregnancy or breastfeeding (lack of safety data), active retinal vasculitis with non-perfusion, and inability to attend the re-implantation and IOP monitoring schedule. Suitability is confirmed only after a full consultant medical retina assessment with OCT and lens status review.

NHS versus private Ozurdex

Ozurdex is routinely available on the NHS via medical retina services under NICE Technology Appraisals TA349 (DMO pseudophakic and phakic second-line), TA229 (RVO macular oedema) and TA460 (posterior uveitis). NHS provision is consultant-led, with virtual or face-to-face medical retina triage clinics confirming the indication, the OCT pattern and the prior anti-VEGF response. NHS waits in 2026 from referral to first Ozurdex implant are typically 4 to 8 weeks in well-funded urban services and 8 to 16 weeks in higher-pressure regions, with re-implantation timed against OCT recurrence at 5 to 6 monthly review.

The private route compresses the timeline to typically 1 to 2 weeks from initial consultation to first implant and offers continuity of consultant care from assessment through the year-1 course and lifelong maintenance. Patients with progressing visual loss who do not wish to wait for NHS access, who require continuity of named consultant care for complex DMO, who travel internationally and need coordinated overseas follow-up, or who have private medical insurance that funds the procedure typically choose the private pathway. The same evidence-based protocols and pivotal trial evidence apply to both NHS and private care.

Private medical insurance cover for Ozurdex

Ozurdex is funded by the major UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) for licensed indications (DMO, RVO macular oedema, non-infectious posterior uveitis) with pre-authorisation, provided that the policy covers chronic eye conditions and that the consultant medical retina specialist is recognised by the insurer. The CCSD procedure codes typically used are C79.4 (intravitreal injection) with the appropriate drug-specific code, plus the consultant assessment code and an OCT macular imaging code if not already bundled.

Each PMI provider sets its own annual injectables/implants benefit limit and may apply an excess; pre-authorisation requires documentation of the diabetic retinopathy stage (or RVO/uveitis diagnosis), the OCT central subfield thickness, the BCVA, the lens status and the clinical justification for Ozurdex (anti-VEGF non-response, pseudophakic eye, vitrectomised eye, inflammatory OCT features, cardiovascular contraindications to anti-VEGF). The clinic team prepares the pre-authorisation package on the patient's behalf and confirms cover in writing before booking the first implant.

Risks and side-effects of Ozurdex

Ozurdex is one of the safer intravitreal interventions in 2026, but it is a steroid implant and the realistic risks should be set out honestly:

• Procedural risks (intravitreal injection):
  • Endophthalmitis — less than 0.05 per cent per injection with povidone iodine 5 per cent preparation; the single most important infection-prevention step is the povidone iodine pre-injection prep.
  • Sterile intra-ocular inflammation — 1 to 2 per cent of injections; usually self-limiting with topical steroid.
  • Retinal detachment — rare, <0.1 per cent per injection; risk higher in vitrectomised and aphakic eyes.
  • Vitreous haemorrhage — rare, <0.5 per cent per injection.
  • Subconjunctival haemorrhage — common (~10 per cent per injection), cosmetic only, resolves spontaneously over 1 to 2 weeks.
  • Transient post-injection IOP spike — common, usually settles within minutes; transiently checked by indirect ophthalmoscopy and tonometry.
• Drug-specific risks (sustained-release dexamethasone):
  • Cataract progression in phakic eyes — 60 to 70 per cent over 3 years in MEAD (vs 21 per cent sham). Typically requires phacoemulsification cataract surgery at some point in the maintenance course; pseudophakic patients are not penalised by this.
  • Intra-ocular pressure rise >25 mmHg — 15 to 30 per cent of injections; almost all (>95 per cent) controllable with topical IOP-lowering drops (latanoprost, dorzolamide-timolol). Less than 1 per cent require incisional glaucoma surgery.
  • Steroid-induced glaucoma — in patients with pre-existing ocular hypertension or open-angle glaucoma, Ozurdex should be used with caution and close IOP monitoring at week 4 to 6 post-implant.
  • Implant migration into anterior chamber — rare (<0.5 per cent), higher risk in aphakic eyes, post-vitrectomy eyes with zonular weakness, or eyes with compromised iris-lens diaphragm; managed by repositioning or explantation.
  • Reactivation of ocular herpes — possible in patients with prior herpetic keratitis or uveitis; check history and consider antiviral prophylaxis.
• Systemic risks — intravitreal Ozurdex produces only trace systemic dexamethasone exposure; systemic steroid side effects (hyperglycaemia, hypertension, osteoporosis, immunosuppression) are not expected from the intravitreal route, in marked contrast to oral or intravenous steroid.
• Treatment burden — 2 to 3 implants in year 1 and 2 implants per year in maintenance; minimum 4 visits per year (assessment, implant, 4-week check, OCT review); IOP and cataract monitoring at each visit; lifelong follow-up for diabetic retinopathy progression.

The overall safety record of Ozurdex is excellent in experienced UK hands; serious sight-threatening complications are minimised by povidone iodine prep, careful technique with the 22-gauge applicator, appropriate lens-status selection (preferring pseudophakic patients), and disciplined IOP monitoring at week 4 to 6 post-implant. The realistic 2-year burden is materially lower than monthly anti-VEGF and the visual outcomes are competitive in well-selected patients.

Recovery and the OCT-guided re-implantation pathway

• Day 0 (implant day) — 60 to 90 minute appointment; 5 to 10 minutes of topical anaesthetic instillation, povidone iodine prep, sterile drape and lid speculum; the 22-gauge applicator procedure itself takes seconds; immediate post-injection IOP and vision check. Discharge with a topical antibiotic (chloramphenicol four times daily for 24 to 48 hours per local protocol) and a 7-day endophthalmitis symptom warning. No driving for 24 hours after pupil dilation.
• Day 1 to week 1 — transient floaters (the implant rod is visible in the inferior vitreous on direct ophthalmoscopy) for several days; transient mild blurred vision; no specific posturing or activity restriction beyond avoiding eye rubbing in the first 24 hours.
• Week 4 OCT review — consultant retina-led OCT macula and IOP check; central subfield thickness typically reduces by 100 to 200 microns from baseline; BCVA frequently improves by 1 to 3 ETDRS lines; IOP spike (if any) typically appears at week 4 to 6 and is managed with topical drops.
• Month 3 review — OCT macula; the implant is still pharmacologically active at month 3 in most eyes; this is the "peak response" window.
• Month 5 to 6 review — OCT macula; if central subfield thickness is rising or BCVA is dropping with re-accumulation of fluid on OCT, re-implant. Some patients are quiescent for longer; OCT-guided re-treatment rather than fixed-interval re-implantation is the modern approach.
• Activity restrictions:
  • No swimming or hot tub for 48 hours.
  • Avoid eye rubbing for 7 days.
  • No contact sports for 48 hours.
  • Otherwise normal activity from day 1.
• Long-term monitoring — OCT macula at every visit; IOP at week 4 to 6 post-implant and at each visit; lens status assessment in phakic patients; HbA1c and blood pressure review with the patient's diabetic team (the most important determinants of long-term DMO outcome are systemic glycaemic and blood-pressure control).
• Cataract pathway in phakic patients — if cataract progresses to visually significant level (typically 12 to 24 months after the first implant in younger phakic patients), phacoemulsification cataract surgery is coordinated between the retina specialist and a cataract surgeon; the patient becomes pseudophakic and Ozurdex maintenance continues more comfortably.

How to choose a UK clinic for private Ozurdex DMO treatment

• CQC registration and named consultant medical retina specialist — verify both the centre's CQC registration and the consultant's individual GMC entry with medical retina fellowship and documented diabetic eye disease practice.
• Per-consultant intravitreal volume — ask for the consultant's annual intravitreal injection volume (target ≥500 per year including Ozurdex) and the centre's endophthalmitis rate per injection (should be at or below the published 0.05 per cent benchmark with povidone iodine prep).
• OCT and OCT angiography included — OCT macula at every visit and OCT-A where indicated should be in the package, not separately charged.
• Povidone iodine 5 per cent standard — non-negotiable; absence of povidone iodine prep is a red flag.
• 4-week post-implant OCT and IOP review included — built into the per-implant fee.
• Lifelong diabetic retinopathy follow-up — the consultant should set out a written plan for years 2 to 5 with OCT and IOP monitoring intervals.
• Coordination with the patient's diabetic team — the clinic should communicate HbA1c, blood pressure and lipid targets with the patient's diabetic physician; systemic control is at least as important as the implant.
• Itemised written quotation — valid 60 days, with itemised components (consultant fee, OCT, the Ozurdex implant, 4-week follow-up, IOP medications if needed).
• Insurance pre-authorisation support — the team should prepare the PMI pre-authorisation letter on your behalf and confirm cover in writing before booking.
• Same-consultant continuity — the consultant implanting Ozurdex should also be the one reviewing OCT at every visit; DMO management is too dependent on serial OCT interpretation for shared follow-up.

Frequently asked questions

How much does a private Ozurdex implant for diabetic macular oedema cost in the UK in 2026?

UK 2026 self-pay private Ozurdex (dexamethasone 0.7 mg PLGA biodegradable intravitreal implant) costs 1,800 to 2,800 pounds per implant at CQC-registered London medical retina centres, all-inclusive. The fee covers the consultant medical retina assessment, OCT macula imaging (and OCT angiography where indicated), the 22-gauge applicator procedure under topical anaesthetic, the implant itself, the immediate post-injection IOP and vision check, and a 4-week follow-up OCT review. A typical year 1 course of 2 to 3 implants totals 3,600 to 8,400 pounds; year 2+ maintenance of 2 implants per year is 3,600 to 5,600 pounds annualised.

What is Ozurdex and how is it different from anti-VEGF injections?

Ozurdex is a biodegradable sustained-release intravitreal implant containing 700 micrograms of dexamethasone in a poly-lactic-co-glycolic acid (PLGA) rod that releases the steroid over approximately 4 to 6 months. Dexamethasone suppresses VEGF, IL-6, IL-8, MCP-1, ICAM-1 and TNF-alpha, restoring the blood-retinal barrier through a multi-pathway anti-inflammatory mechanism. Anti-VEGF agents (faricimab, aflibercept, ranibizumab, brolucizumab, bevacizumab) target VEGF-A specifically and require monthly to 4-monthly injections. The trade-off: anti-VEGF has no cataract or IOP penalty but a higher injection burden; Ozurdex has materially lower injection burden but 60 to 70 per cent cataract progression in phakic eyes over 3 years and 15 to 30 per cent IOP rise per implant (almost all controllable with topical drops).

How often will I need Ozurdex implants?

The Ozurdex implant releases dexamethasone over approximately 4 to 6 months. The typical OCT-guided maintenance schedule is 2 to 3 implants in year 1 (loading at baseline, repeat at month 4 to 6 if OCT shows recurrent macular thickening) and 2 implants per year in maintenance years 2+. Vitrectomised eyes may clear the implant slightly faster; some quiescent patients are stable for 6 to 9 months between implants. OCT-guided re-treatment rather than fixed-interval re-implantation is the modern approach.

Does the NHS pay for Ozurdex?

Yes. Ozurdex is routinely funded on the NHS under NICE Technology Appraisal TA349 (DMO in pseudophakic eyes and as second-line in phakic eyes inadequately responsive to non-corticosteroid therapy), TA229 (macular oedema secondary to branch and central retinal vein occlusion), and TA460 (non-infectious posterior uveitis). NHS waits in 2026 from referral to first implant are typically 4 to 8 weeks in well-funded urban services and 8 to 16 weeks in higher-pressure regions; re-implantation is timed against OCT recurrence at 5 to 6 monthly review.

Ozurdex versus anti-VEGF for DMO — which is better?

In phakic eyes, anti-VEGF (faricimab, aflibercept, ranibizumab) is first-line per most international guidelines. Ozurdex is first-line steroid in pseudophakic and vitrectomised DMO, and a strong second-line option in phakic eyes inadequately responsive to anti-VEGF or in patients with significant injection-clinic burden, cardiovascular contraindications, or inflammatory OCT biomarkers (hyperreflective foci, DRIL). The DRCR Protocol U sub-analysis (2018) showed combined ranibizumab plus Ozurdex achieved superior anatomic dry-out but not visual gain over ranibizumab alone, with higher IOP rise. The decision is individualised.

Is Ozurdex safe? What are the main risks?

Ozurdex has an excellent safety profile in experienced UK hands. The most important risks are cataract progression in phakic eyes (60 to 70 per cent over 3 years in MEAD), IOP rise greater than 25 mmHg (15 to 30 per cent per implant; almost all controllable with topical drops, less than 1 per cent require glaucoma surgery), endophthalmitis (less than 0.05 per cent per injection with povidone iodine prep), sterile intra-ocular inflammation (1 to 2 per cent per injection), and rare implant migration to the anterior chamber in aphakic or compromised-zonule eyes (less than 0.5 per cent). Systemic steroid side effects are not expected from the intravitreal route. Pseudophakic patients are not penalised by the cataract risk; phakic patients should be counselled that phacoemulsification cataract surgery will likely be needed within 1 to 3 years of starting Ozurdex.

Will my private medical insurance cover Ozurdex?

Yes — Bupa, AXA Health, Aviva, Vitality and WPA cover Ozurdex for licensed indications (DMO under TA349, RVO macular oedema under TA229, non-infectious posterior uveitis under TA460) with pre-authorisation, provided the policy covers chronic eye conditions and the consultant medical retina specialist is recognised. The CCSD procedure code is typically C79.4 (intravitreal injection) with the Ozurdex drug code. Pre-authorisation requires documented diagnosis, OCT central subfield thickness, BCVA, lens status and clinical justification for Ozurdex over anti-VEGF (pseudophakia, vitrectomy, anti-VEGF non-response, inflammatory OCT features, or cardiovascular contraindications). The clinic team prepares the pre-authorisation package on your behalf.

Can Ozurdex be used for retinal vein occlusion or uveitis?

Yes. Ozurdex is licensed for three indications: diabetic macular oedema (NICE TA349), macular oedema secondary to branch or central retinal vein occlusion (NICE TA229, supported by the GENEVA phase 3 trial, Haller et al., Ophthalmology 2010), and non-infectious uveitis affecting the posterior segment (NICE TA460, supported by HURON, Lowder et al., 2011). The dosing schedule is the same (single implant releasing dexamethasone over 4 to 6 months, OCT-guided re-implantation). Outcomes in RVO and uveitis are often more dramatic than in DMO because inflammation is the dominant pathology.

How quickly does Ozurdex work?

OCT central subfield thickness typically reduces by 100 to 200 microns within the first 4 weeks after implantation, and BCVA frequently improves by 1 to 3 ETDRS lines (5 to 15 letters) within 4 to 8 weeks. The peak anatomic and visual response is generally at month 2 to 3. In MEAD, mean BCVA gain at 3 years was approximately 3 letters in the Ozurdex arm versus 2 letters sham, with 22.2 per cent of patients gaining 15 letters or more. Real-world outcomes are often better when Ozurdex is used as switch therapy in suboptimal anti-VEGF responders with strong inflammatory OCT features.

What happens at the Ozurdex implant appointment?

Total appointment time is 60 to 90 minutes. After pupil dilation, the consultant retina specialist confirms suitability with OCT, then in the clean room or sterile minor procedure room: topical anaesthetic drops (proxymetacaine, tetracaine) are instilled three to four times over 5 to 10 minutes; povidone iodine 5 per cent is applied to the conjunctiva and lid margin; sterile drape and lid speculum applied; the injection site is marked 3.5 to 4.0 millimetres posterior to the limbus in the supero-temporal or infero-temporal quadrant; the Ozurdex 22-gauge applicator is inserted through the pars plana and the implant is released into the vitreous cavity; the needle is withdrawn; immediate post-injection IOP measurement and indirect ophthalmoscopy to confirm central retinal artery perfusion. Discharge with topical antibiotic and a 7-day endophthalmitis symptom warning.

Will I get cataract from Ozurdex?

If you are phakic (have your natural lens), Ozurdex significantly accelerates cataract progression. In MEAD, 60 to 70 per cent of phakic eyes required cataract surgery within 3 years of starting Ozurdex (versus 21 per cent in the sham group). The cataract is typically posterior subcapsular and develops over 12 to 36 months. The pragmatic plan in phakic patients is to start Ozurdex, accept that phacoemulsification cataract surgery will likely be needed within 1 to 3 years, schedule the cataract surgery once visually significant, and continue Ozurdex maintenance more comfortably as a pseudophake. Pseudophakic patients are not penalised by the cataract risk.

Will Ozurdex raise my eye pressure?

Approximately 15 to 30 per cent of Ozurdex implants are followed by a clinically significant IOP rise greater than 25 mmHg, typically appearing at week 4 to 6 post-implant. The rise is almost always (greater than 95 per cent) controllable with topical IOP-lowering drops (latanoprost, dorzolamide-timolol, brimonidine). Less than 1 per cent of patients require incisional glaucoma surgery. The IOP rise typically settles as the implant clears at 4 to 6 months, but some patients require ongoing IOP-lowering therapy through the maintenance pathway. Patients with pre-existing ocular hypertension or open-angle glaucoma require closer IOP monitoring and may benefit from prophylactic IOP-lowering drops.

When can I drive after an Ozurdex implant?

Most patients return to driving the day after the implant once pupil dilation has fully resolved, provided the operated eye is comfortable and vision is sufficient. Patients with only one functional eye, with significant visual field loss, or who hold a Group 2 (HGV or PSV) licence should not drive until specifically cleared by the consultant. Transient floaters (the implant rod is visible in the inferior vitreous) and mild blurred vision for several days are normal and do not preclude driving once dilation has resolved and the patient feels safe to drive. The 0800 852 7782 advice line is available for individual queries. See also our wider anti-VEGF injections overview for related post-procedure guidance.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with medical retina subspecialty interest. Pricing reflects a CQC-registered UK medical retina sample audited against published 2024 to 2026 self-pay tariffs from the major UK medical retina providers. Clinical statements are anchored on:

• Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (MEAD). Ophthalmology 2014; 121(10): 1904–1914.
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121(12): 2473–2481.
• Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion (GENEVA). Ophthalmology 2010; 117(6): 1134–1146.
• Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients (CHAMPLAIN). Retina 2011; 31(5): 915–923.
• Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis (HURON). Archives of Ophthalmology 2011; 129(5): 545–553.
• Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR Network Phase 2 randomized clinical trial (Protocol U). JAMA Ophthalmology 2018; 136(1): 29–38.
• Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J. Real-world experience with 0.2 microgram/day fluocinolone acetonide intravitreal implant (Iluvien) in the United Kingdom. Eye 2017; 31(12): 1707–1715.
• Iglicki M, Busch C, Zur D, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: International Retina Group Real-Life Study. Retina 2019; 39(1): 44–51.
• NICE Technology Appraisal TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema (July 2015, updated TA824 review).
• NICE Technology Appraisal TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (July 2011).
• NICE Technology Appraisal TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (July 2017).
• Royal College of Ophthalmologists Diabetic Eye Disease Guidelines (latest edition).
• American Academy of Ophthalmology Diabetic Retinopathy Preferred Practice Pattern 2024.
• EURETINA Treatment Recommendations for Diabetic Macular Oedema (latest update).
• Care Quality Commission (CQC) inspection reports for major UK medical retina units (Moorfields Eye Hospital, Royal Free Hospital, Cromwell Hospital, Optegra Eye Hospital).
• General Medical Council (GMC) Good Medical Practice and consent guidance.

This page is editorial and educational. It is not personalised medical advice. Ozurdex suitability can only be confirmed by an in-person medical retina consultation with OCT, OCT angiography and lens-status assessment.

Book your UK Ozurdex DMO consultation

Speak directly to a UK GMC-registered consultant ophthalmologist with medical retina subspecialty interest. Same-week consultation slots are usually available. OCT macula and OCT angiography are included in the consultation. Confidential, no-obligation review of whether Ozurdex, anti-VEGF (faricimab Vabysmo, aflibercept Eylea, ranibizumab Lucentis), Iluvien or combined treatment is right for your eye.

Related reading: Private faricimab (Vabysmo) injection cost UK · Private anti-VEGF wet AMD injections London · Macular degeneration condition guide · Macular degeneration treatments overview